Court rules against Sanofi's Lovenox in Amphastar, Teva challenge

02/11/2007 | Bloomberg Businessweek · Wall Street Journal, The

A U.S. court cleared the way for a generic version of Lovenox, a Sanofi-Aventis blood thinner, when it ruled the firm engaged in inequitable conduct for its original patent. Sanofi, which may appeal the verdict, has a patent that does not expire until 2012, but Amphastar Pharmaceuticals and Teva Pharmaceutical Industries sued to be able to sell generics before then, even though no generic copy has been approved by the FDA.

View Full Article in:

Bloomberg Businessweek · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA